Kanes Stepl Form 4	nen								
February 15	5, 2019								
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION							OMB APPROVAL		
	UNITED	STATES		RITIES A shington			E COMMISSION	NOMB Number:	3235-0287
Check ti if no lor subject Section Form 4 Form 5 obligation may con <i>See</i> Inst	nger to 16. or Dins ttinue. Section 17(STATEMENT OF CHANGE SE Filed pursuant to Section 16(a) Section 17(a) of the Public Utility 30(h) of the Invest				ties Excha npany Act	Estimated burden hou response	Estimated average burden hours per response 0.5	
1(b).					_				
(Print or Type	Responses)								
Varia Charles			2. Issuer Name and Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer		
			Sage T	herapeuti	cs, Inc. [SAGE]	(Che	ck all applicabl	e)
(Last) (First) (Middle) C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET			3. Date of Earliest Transaction (Month/Day/Year) 02/13/2019				Director 10% Owner Officer (give title Other (specify below) below) Chief Medical Officer		
			4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRIE	OGE, MA 02142						Form filed by Person	More than One R	eporting
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	Acquired, Disposed of	of, or Beneficia	lly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	Date, if	3. Transactio Code (Instr. 8)	Disposed	(A) or of (D) 4 and 5)	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	Amount	(A) or (D) Price	Transaction(s) (Instr. 3 and 4)		
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly.		
							spond to the collect tained in this form		SEC 1474 (9-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S



Signatures

/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Stephen Kanes	02/15/2019
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities awarded on February 13, 2019 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock
 (1) Option and Incentive Plan. Options to purchase 4,750 shares of common stock shall vest on the one year anniversary of February 13, 2019, with 14,250 shares vesting in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.